Slide 1: Announcement of Q1 2008 Results and Confirmation of FY 2008 Guidance
Announcement of Q1 2008 Results and Confirmation of FY 2008 Guidance Conference Call April 14, 2008 | 3.00 p.m. CEST Dr. Axel Herberg, CEO Hans-Jürgen Wiecha, CFO 0
Slide 2: Agenda
Agenda Business Highlights Q1 2008 Dr. Axel Herberg, CEO Financial Overview Q1 2008 Hans-Jürgen Wiecha, CFO Confirmation of Guidance FY 2008 Dr. Axel Herberg, CEO 1
Slide 3: Success story of 2007 continues in Q1 2008
Success story of 2007 continues in Q1 2008 Ongoing strong demand for Gerresheimer products in pharma & life science and cosmetics industry Gerresheimer continues to grow above market level Acquisitions of EDP and Allplas further enlarge Gerresheimer’s product portfolio and geographic reach Net sales
Slide 4: Continued positive momentum across all divisions
Continued positive momentum across all divisions Tubular Glass: Ongoing strong demand for RTF-syringes Continued high sales of vials in America New greenfield plant in China with western production standard under construction Plastic Systems: Strong growth in medical plastic systems New segment “pen
Slide 5: Gerresheimer's business remains strong despite volatilities in the financial markets
Gerresheimer´s business remains strong despite volatilities in the financial markets Growth pattern strongly related to worldwide pharma and healthcare demand Accelerating pace in drug development Strong growth in world population with more people having access to healthcare Increasing average life
Slide 6: Agenda
Agenda Business Highlights Q1 2008 Dr. Axel Herberg, CEO Financial Overview Q1 2008 Hans-Jürgen Wiecha, CFO Confirmation of Guidance FY 2008 Dr. Axel Herberg, CEO 5
Slide 7: Group: Continued growth and margin enhancement
Group: Continued growth and margin enhancement Net sales and adjusted EBITDA =m Net sales growth at Adj. EBITDA margin: constant exchange Q1 2008: 18.0% rate: 21.8% Q1 2007: 17.6% Strong growth in net sales +18.2% primarily due to sound 239.1 development of pharma and 202.3 cosmetics markets Higher
Slide 8: Tubular Glass: Ongoing strong demand for RTF-syringes
Tubular Glass: Ongoing strong demand for RTF-syringes Net sales and adjusted EBITDA =m Net sales growth at Adj. EBITDA margin: constant exchange Q1 2008: 24.0% rate: 14.6% Q1 2007: 24.9% Sales increase fueled by strong revenue growth in RTF-syringes (+68%) strong sales of vials in +9.1% America 65.7
Slide 9: Plastic Systems: Continued sales growth in core segments coupled with margin improvement
Plastic Systems: Continued sales growth in core segments coupled with margin improvement Net sales and adjusted EBITDA =m Net sales growth at Adj. EBITDA margin: constant exchange Q1 2008: 18.3% Strong growth generated by Q1 2007: 17.2% rate: 36.5% prospering sales in inhalation and diabetes care as
Slide 10: Moulded Glass: Sales growth exceeds market growth
Moulded Glass: Sales growth exceeds market growth Net sales and adjusted EBITDA =m Net sales growth at Adj. EBITDA margin: constant exchange Q1 2008: 20.6% rate: 7.8% Q1 2007: 18.0% Above market sales growth due +5.0% to strong demand for 73.9 77.6 pharma bottles in the US and Europe cosmetics in th
Slide 11: Life Science Research: Foundation for growth established
Life Science Research: Foundation for growth established Net sales and adjusted EBITDA =m Net sales growth at Adj. EBITDA margin: constant exchange Q1 2008: 11.1% rate: >100% Q1 2007: 10.7% Significant net sales expansion through merger with life 21.8 science business of Thermo +81.7% Fisher 12.0 Sl
Slide 12: Profit growth exceeds growth in net sales
Profit growth exceeds growth in net sales =m Q1 2008 Q1 2007 FY 2007 Net sales 239.1 202.3 +18.2% 957.7 Adjusted EBITDA1 43.0 35.7 +20.4% 181.6 Margin 18.0% 17.6% 19.0% Adjusted EBITA 25.5 21.9 +16.4% 116.6 Margin 10.7% 10.8% 12.2% Profit from operations 14.9 11.4 +30.7% 53.3 Net income 2.5 -4.0 >10
Slide 13: Strong balance sheet and markedly enhanced cash flows set the stage for future growth
Strong balance sheet and markedly enhanced cash flows set the stage for future growth Q1 as of Q1 as of FY 2007 as of =m Feb 29, 2008 Feb 28, 2007 Nov 30, 2007 Equity 505.8 -30.9 >100% 505.1 Equity ratio in % 34.2 n/a 35.0 Net working capital1 220.1 189.5 +16.1% 194.5 in % of LTM net sales 22.1 27.1
Slide 14: Agenda
Agenda Business Highlights Q1 2008 Dr. Axel Herberg, CEO Financial Overview Q1 2008 Hans-Jürgen Wiecha, CFO Confirmation of Guidance FY 2008 Dr. Axel Herberg, CEO 13
Slide 15: Confirmation of Guidance FY 2008
Confirmation of Guidance FY 2008 Growth of approx. 13 – 15%1 (at constant exchange rate 14-16%) Net Sales Mid 19% Adj. EBITDA margin Expected investments of (105m – (110m Capex Ongoing market observation for value-accretive M&A transactions Portfolio optimization 1 Exchange rate assumption for the F
Slide 16: Financial Calendar 2008 / 2009
Financial Calendar 2008 / 2009 May 23, 2008 Annual General Meeting July 15, 2008 Interim Report 2nd Quarter 2008 October 15, 2008 Interim Report 3rd Quarter 2008 October 23+24, 2008 Capital Markets Day 2008 February 17, 2009 Full Year Results 2008 15
Slide 17: Contact Details
Contact Details Investor Relations Phone: +49 211 6181 – 257 Fax: +49 211 6181 – 121 E-mail: investorrelations@gerresheimer.com Please visit our IR website: www.gerresheimer.com/ir 16
Slide 18: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or